Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

National Institute on Drug Abuse (NIDA)17 enrolled

Overview

The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.

This is a double-blind, placebo-controlled human laboratory clinical pharmacology study to assess potential interactions between intravenous d-methamphetamine infusion and treatment with oral aripiprazole.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Enrollment

Conditions

Amphetamine-Related Disorders

Interventions

AripiprazoleDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Must meet DSM-4 criteria for methamphetamine abuse or dependence and are non-treatment seeking. * Ability to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures. Exclusion Criteria: * Please contact the site for more information.

Locations (2)

UCLA Integrated Substance Abuse Program

Los Angeles, California, United States

New York University, School of Medicine

New York, New York, United States

Outcomes

Primary Outcomes

Adverse effect measures

pharmacokinetic assessment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.